GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 109-118

  Springer, Aaron D ^a   Dowdy, Steven F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinical trials; liver; N acetylgalactosamine

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; N ACETYLGALACTOSAMINE; N ACETYLGALACTOSAMINE SMALL INTERFERING RNA CONJUGATE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GLYCOCONJUGATE; NANOPARTICLE;

CLINICAL TRIAL (TOPIC); CONJUGATE; DRUG DESIGN; HUMAN; LIVER; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RNAI THERAPEUTICS; CHEMISTRY; ENDOCYTOSIS; ENDOSOME; GENE TRANSFER; GENETICS; LIVER CELL; METABOLISM; NEOPLASM; PARKINSON DISEASE; PATHOLOGY; VIROLOGY; VIRUS INFECTION;

ACETYLGALACTOSAMINE; ASIALOGLYCOPROTEIN RECEPTOR; CLINICAL TRIALS AS TOPIC; ENDOCYTOSIS; ENDOSOMES; GENE TRANSFER TECHNIQUES; GLYCOCONJUGATES; HEPATOCYTES; LIVER; NANOPARTICLES; NEOPLASMS; PARKINSON DISEASE; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 85048368218     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2018.0736     Document Type: Review

References (123)

1. Dowdy SF. (2017). Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35:222-229.
2. Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518-6548.
3. Khvorova A and JK Watts. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238-248.
4. Zimmermann TS, AC Lee and A Akinc. (2006). RNAimediated gene silencing in non-human primates. Nature 44:111-114.
5. Gantier MP and BR Williams. (2007). The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 18:363-371.
6. Rerrig GR and MA Behlke. (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20:483-512.
7. Morell AG, G Gregoriadis, IH Scheinberg, J Hickman and G Ashwell. (1971). The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246:1461-1467.
8. Nair JK, JLWilloughby, A Chan, K Charisse, MR Alam, Q Wang, M Hoekstra, P Kandasamy, AV Kel'in, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958-16961.
9. Grewal PK. (2010). The Ashwell-Morell receptor. Methods Enzymol 479:223-241.
10. Stockert RJ, AG Morell and IH Scheinberg. (1974). Mammalian hepatic lectin. Science 186:365-366.
11. Anonymous. (2008). Gilbert Ashwell: sweet on science. Nat Med 14:608.
12. Morell AG, CJ van den Hamer, IH Scheinberg and G Ashwell. (1966). Physical and chemical studies on ceruloplasmin. IV. Preparation of radioactive, sialic acid-free ceruloplasmin labeled with tritium on terminal d-galactose residues. J Biol Chem 241:3745-3749.
13. Morell AG, RA Irvine, I Sternlieb, H Scheinberg and G Ashwell. (1968). Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 243:155-159.
14. Pricer WE, Jr., and G Ashwell. (1971). The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem 246:4825-4833.
15. Morell AG and IH Scheinberg. (1972). Solubilization of hepatic binding sites for asialo-glycoproteins. Biochem Biophys Res Commun 48:808-815.
16. Sarkar M, J Liao, EA Kabat, T Tanabe and G Ashwell. (1979). The binding site of rabbit hepatic lectin. J Biol Chem 254:3170-3174.
17. Novogrodsky A and G Ashwell. (1977). Lyphocyte mitogenesis induced by a mammalian liver protein that specifically binds desialylated glycoproteins. Cell Biol 74:676-678.
18. Hickman J, G Ashwell, AG Morell, CJ van den Hamer and IH Scheinberg. (1970). Physical and chemical studies on ceruloplasmin. 8. Preparation of N-acetylneuraminic acid- 1-14C-labeled ceruloplasmin. J Biol Chem 245:759-766.
19. Van den Hamer CJA, AG Morell, IH Scheinberg, J Hickman and G Ashwell. (1970). Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. J Biol Chem 245:4397-4402.
20. van Lenten L and G Ashwell. (1972). The binding of desialylated glycoproteins by plasma membranes of rat liver. Development of a quantitative inhibition assay. J Biol Chem 247:4633-4640.
21. Kawaguchi K, M Kuhlenschmidt, S Roseman and YC Lee. (1980). Synthesis of some cluster galactosides and their effect on the hepatic galactose binding system. Arch Biochem Biophys 205:388-395.
22. Steer CJ and G Ashwell. (1980). Studies on a mammalian hepatic binding protein specific for asialoglycoproteins. Evidence for receptor recycling in isolated rat hepatocytes. J Biol Chem 255:3008-3013.
23. Lee YC, RR Townsend, MR Hardy, J lönngren, J Arnarp, M Haralsson and H Lönn. (1982). Binding of synthetic oligosaccharides to hepatic Gal/GalNAc lectin. J Biol Chem 258:199-202.
24. Baenziger AU and D Fiete. (1980). Galactose and Nacetylgalactosamine- specific endocytosis of glycopeptides by isolated rate hepatocytes. Cell 22:611-620.
25. Lee YC and RT Lee. (2008). Interactions of oligosaccharides and glycoproteins with hepatic carbohydrate receptors. In: Carbohydrates in Chemistry and Biology. Vol. 4. Ernst B, GW Hart, P Sináy, eds. Wiley-VCH Verlag GmBh, Weinheim, Germany, pp 549-561.
26. Meier M, MD Bider, VN Malashkevich, M Spiess and P Burkhard. (2000). Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol 300:857-865.
27. Mammen M, S-K Choi and GM Whitesides. (1998). Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Agnew Chem Int Ed 37:2754-2794.
28. D'Sousa AA and PV Devarajan. (2015). Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications. J Control Release 203:126-139.
29. Schwartz AL, A Marshak-Rothstein, D Rup and HF Lodish. (1981). Identification and quantification of the rate hepatocyte asialoglycoprotein receptor. Proc Natl Acad Sci U S A 78:3348-3352.
30. Schwartz AL, D Rup and HF Lodish. (1980). Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem 255:9033-9036.
31. Pricer WE and G Ashwell. (1976). Subcellular distribution of a mammalian hepatic binding protein specific for asialoglycoproteins. J Biol Chem 251:7539-7544.
32. Kolb-Bachofen V. (1981). Hepatic receptor for asialoglycoproteins. Ultrastructural demonstration of ligandinduced microaggregation of receptors. Biochim Biophys Acta 645:293-299.
33. Weigel PH. (1980). Rat hepatocytes bind to synthetic galactoside surfaces via a patch of asialoglycoprotein receptors. J Cell Biol 87:855-861.
34. Schwartz AL, SE Fridovich and HF Lodish. (1982). Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem 257:4230-4237.
35. Stockert RJ, HB Haimes, AG Morell, PM Novikoff, AB Novikoff, N Quintana and I Sternlieb. (1980). Endocytosis of asialoglycoprotein-enzyme conjugates by hepatocytes. Lab Invest 43:556-563.
36. Tanabe T, WE Pricer, Jr., and G Ashwell. (1979). Subcellular membrane topology and turnover of rat hepatic binding protein specific for asialoglycoproteins. J Biol Chem 254:1038-1043.
37. Gregoriadis G, AG Morell, I Sternlieb and IH Scheinberg. (1970). Catabolism of desialylated ceruloplasmin in the liver. J Biol Chem 245:5833-5837.
38. Bridges K, J Harford, G Ashwell and RD Klausner. (1982). Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci U S A 79:350-354.
39. Wall DA, G Wilson and AL Hubbard. (1980). The galactose-specific recognition system of mammalian liver: the route of ligand internalization in rat hepatocytes. Cell 21:79-93.
40. Geuze HJ, JW Slot, GJ Strous, HF Lodish and AL Schwartz. (1983). Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy and during receptor-mediated endocytosis. Cell 32:277-287.
41. Rogers JC and S Kornfield. (1971). Hepatic uptake of proteins coupled to fetuin glycopeptide. Biochem Biophys Res Commun 45:622-629.
42. Wilson G. (1978). Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J Biol Chem 253:2070-2072.
43. Fiume L, A Mattioli, PG Balboni, M Tognon, G Barbanti- Brodano, J de Vries and T Wieland. (1979). Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 103: 47-51.
44. Fiume L, A Mattioli, C Busi, PG Balboni, G Barbanti- Brodano, J de Vries, R Altmann and T Wieland. (1980). Selective inhibition of ectromelia virus DNA synthesis in hepatocytes by adenine-9-b-d-arabinofuranoside (ARAA) and adenine-9-b-arabinofuranoside 5′-monophosphate (ARA-AMP) conjugated to asialofetuin. FEBS Lett 116: 185-188.
45. Attie AD, RC Pittman and D Steinberg. (1980). Metabolism of native and lactosylated human low density lipoprotein: evidence for two pathways for catabolism of exogenous proteins in rat hepatocytes. Proc Natl Acad Sci U S A 77:5923-5927.
46. Simpson DL, DB Cawley and HR Herschman. (1982). Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin and diphtheria toxin. Cell 29:469-473.
47. Rensen PCN, SH van Leeuwen, LA Sliedregt, TJC van Berkel and EA Biessen. (2004). Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J Med Chem 47:5798-5808.
48. Seymour LW, DR Ferry, D Anderson, S Hesslewood, PJ Julyan, R Poyner, J Doran, AM Young, S Burtles, DJ Kerr and Cancer Research Campaign Phase I/II Clinical Trials Committee. (2002). Hepatic drug targeting: phase I evaluation of polymer bound doxorubicin. J Clin Oncol 20: 1668-1676.
49. Rohlff C, SA Watson, TM Morris, L Skelton, AL Jackman and MJ Page. (1999).Anovel, orally administered nucleoside analogue, OGT 719, inhibits liver invasive growth of human colorectal tumor, C170HM2. Cancer Res 59:1268-1272.
50. Fiume L, C Busi and A Mattioli. (1983). Targeting antiviral drugs by coupling with protein carriers. FEBS Lett 153:6-10.
51. Wu GY and CH Wu. (1987). Receptor-mediated in vitro gene transformation by soluble DNA carrier system. J Biol Chem 262:4429-4432.
52. Wu GY and CH Wu. (1988). Receptor-mediated gene delivery and expression in vivo. J Biol Chem 263:14621-14624.
53. Wu GY and CH Wu. (1988). Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochimie 27: 887-892.
54. Plank C, K Zatloukal, M Cotten, K Mechtler and E Wagner. (1992). Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with artificial terta-antennary galactose ligand. Bioconjug Chem 3:533-539.
55. Merwin JR, GS Noell, WL Thomas, HC Chiou, M De- Rome, TD McKee, GL Spitalny and MA Findeis. (1994). Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor. Bioconjug Chem 5:612-620.
56. Wu GY and CH Wu. (1992). Specific inhibition of hepetitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 267:12436-12439.
57. Hangeland JJ, JT Levis, YC Lee and PO Ts'o. (1995). Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with neoglycopeptide, YEE(ah-GalNAC)3. Bioconjug Chem 6:695-701.
58. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chappell, K Schmidt, C Zhao, M Aghajan, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetylgalactosamine improved potency 10- fold in mice. Nucleic Acid Res 42:8696-8807.
59. Yu RZ, MJ Graham, N Post, S Riney, T Zanardi, S Hall, J Burkey, CS Shemesh, TP Prakash, et al. (2016). Disposition and pharmacology of GalNAc3-conjugated ASO targeting human liopoprotein (a) in mice. Mol Ther Nucleic Acids 5:e317.
60. Biessen EA, H Vietsch, ET Rump, K Fluiter, J Kuiper, MK Bijsterbosch and TJ van Berkel. (1999). Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. J Biol Chem 340:783-792.
61. Wu CH, JM Wilson and GY Wu. (1989). Targeting genes: delivery and persisten expression of a forign gene driven by mammalian regulatory elements in vivo. J Biol Chem 264:16985-16987.
62. Orrantia E and PL Chang. (1990). Intracellular distribution of DNA internalization through calcium phosphate precipitation. Exp Cell Res 190:170-174.
63. Fire A, S Xu, MK Montgomery, SA Kostas, SE Driver and CC Mello. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
64. Elbashir SM, J Harborth, W Lendeckel, A Yalcin, K Weber and T Tuschl. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
65. Ohrt T, J Muetze, P Svoboda and P Schwille. (2012). Intracellular localization and routing of miRNA and RNAi pathway components. Curr Top Med Chem 12:79-88.
66. Schirle NT and IJ MacRae. (2012). The crystal structure of human Argonaute1. Science 336:1037-1040.
67. Schirle NT, J Sheu-Gruttadauria and IJ MacRae. (2014). Structural basis for microRNA targeting. Science 346: 608-613.
68. Salomon WE, SM Jolly, MJ Moore, PD Zamore and V Serebrov. (2015). Single-molecule imaging reveals that Argonaute reshapes the binding properties of its nucleic acid guides. Cell 162:84-95.
69. Iversen F, C Yang, F Dagnæs-Hansen, DH Schaffert, J Kjems and S Gao. (2013). Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3:201-209.
70. Juliano RL, X Ming, K Carver and B Laing. (2014). Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther 24:101-113.
71. Rytler JM and SC Schultz. (1998). Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. EMBO J 17:7505-7513.
72. Hagopian JC, AS Hamil, A van den Berg, BR Meade, A Eguchi, C Palm-Apergiand and SF Dowdy. (2017). Induction of RNAi responses by short left-handed hairpin RNAi triggers. Nucleic Acid Ther 27:260-271.
73. Fitzgerald K, S White, A Borodovsky, BR Bettencourt, A Strahs, V Clausen, P Wijngaard, JD Horton, J Taubel, et al. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41-51.
74. Matranga C, Y Tomari, C Shin, DP Bartel and PD Zamore. (2005). Passenger strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123:607-620.
75. Robbins M, A Judge and I MacLachlan. (2009). SiRNA and innate immunity. Oligonucleotides 19:89-102.
76. Huang Y. (2017). Preclinical and clinical advances of GalNAcdecorated nucleic acid therapeutics. Mol Ther 6:116-132.
77. Huang YY and ZC Liang. (2015). Asialoglycoprotein receptor and its application in liver-targeted drug delivery. Prog Biochem Biophys 42:501-510.
78. Rajeev KG, T Zimmermann, M Manoharan, M Maier, S Kuchimanchi and K Charisse. (2013). Modified RNAi agents. U.S. Patent WO2013074974.
79. MaierM, D Foster, S Milstein, S Kuchimanchi, V Jadhav, K Rajeev, M Manoharan and R Parmar. (2016). Modified double-stranded RNA agents. U.S. Patent WO2016028649.
80. Alnylam. (2014). Advances in delivery of RNAi therapeutics with enhanced stabilization chemistry (ESC)-GalNAc-siRNA conjugates, http://alnylam.com/web/assets/Roundtable-ESCGalNAc-Conjugates-072214.pdf Accessed on April 23, 2018.
81. Schlegel MK, DJ Foster, AV Kel'in, I Zlatev, A Bisbe, M Jayaraman, JG Lackey, KG Rajeev, K Charissé, et al. (2017). Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc 139:8537-8546.
82. Alnylam. (2017). Platform advances in RNAi therapeutics, http://alnylam.com/wp-content/uploads/2017/08/RNAi-Platform-RoundTable-INAL20170823.pdf Accessed on April 23, 2018.
83. Parmar R, JL Willoughby, J Liu, DJ Foster, B Brigham, CS Theile, K Charisse, A Akinc, E Guidry, et al. (2016). 5′-(E)-vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. ChemBioChem 17:985-989.
84. Prakash TP, GA Kinberger, HM Murray, A Chappell, S Riney, MJ Graham, WF Lima, EE Swayze and PP Seth. (2016). Synergistic effect of phosphorothioate, 5′-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg Med Chem Lett 26:2817-2820.
85. Sehgal A, S Barros, L Ivanciu, B Cooley, J Qin, T Racie, J Hettinger, M Carioto, Y Jiang, et al. (2015). An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21:492-497.
86. Rajeev KG, JK Nair, M Jayaraman, K Charisse, N Taneja, J O'Shea, JL Willoughby, K Yucius, T Nguyen, et al. (2015). Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem 16:903-908.
87. Sliedregt LA, PC Rensen, ET Rump, PJ van Santbrink, MK Bijsterbosch, AR Valentijn, GA van der Marel, JH van Boom, TJ van Berkel and EA Biessen. (1999). Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem 42:609-618.
88. Prakash TP, J Yu, MT Migawa, GA Kinberger, WB Wan, ME Østergaard, RL Carty, G Vasquez, A Low, et al. (2016). Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem 59:2718-2733.
89. Migawa MT, TP Prakash, G Vasquez, WB Wan, J Yu, GA Kinberger, ME Østergaard, EE Swayze and PP Seth. (2016). A convenient synthesis of 5′-triantennary N-acetylgalactosamine clusters based on nitromethanetrispropionic acid. Bioorg Med Chem Lett 26:2194-2197.
90. Matsuda S, K Keiser, JK Nair, K Charisse, RM Manoharan, P Kretschmer, CG Peng, AV Kel'in, P Kandasamy, et al. (2015). siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol 10:1181-1187.
91. Sebestyén MG, SC Wong, V Trubetskoy, DL Lewis and CI Wooddell. (2015). Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol Biol 1218:163-186.
92. Zimmermann TS, V Karsten, A Chan, J Chiesa, M Boyce, BR Bettencourt, R Hutabarat, S Nochur, A Vaishnaw and J Gollob. (2017). Clinical proof of concept for a novel hepatocytetargeting GalNAc-siRNA conjugate. Mol Ther 25:71-78.
93. Hawkins PN, Y Ando, A Dispenzeri, A Gonzalez-Duarte, D Adams and OB Suhr. (2015). Evolving landscape in the management of transthyretin amyloidosis. Ann Med 47: 625-638.
94. Butler JS, A Chan, S Costelha, S Fishman, JLS Willoughby, TD Borland, S Milstein, DJ Foster, P Gonçalves, et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 23:109-118.
95. Alnylam. (2017). Investigation of mortality imbalance in Revusiran phase 3 study, ENDEAVOUR, http://investors.alnylam.com/static-files/c8f6284e-841b-4f0e-846d-046aa-73824b6 Accessed on April 23, 2018.
96. Alnylam. (2018). Alnylam presents new clinical results from the Apollo Phase 3 study of Patisiran at the 16th international symposium on amyloidosis, http://investors.alnylam.com/news-releases/news-release-details/alnylampresents-new-clinical-results-apollo-phase-3-study Accessed on April 23, 2018.
97. Taubel J, T Zimmermann, V Karsten, C Martinez, A Chan, Y Wang, H Attarwala, J Gollob and J Vest. (2018). Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis, http://alnylam.com/wp-content/uploads/2018/03/10.-TTR-SCO2-FINAL.pdf Accessed on April 23, 2018.
98. Alnylam. (2018). Nonclinical research published in nature communications describing optimization of GalNAcsiRNA conjugates to minimize off-target potential and maximize therapeutic index, http://alnylam.com/2018/02/19/nonclinical-research-published-in-nature-communicationsdescribing-optimization-of-galnac-sirna-conjugates-to-minimize-off-target-potential-and-maximize-therapeutic-index/Accessed on April 23, 2018.
99. Yasuda M, L Gan, B Chen, S Kadirvel, C Yu, JD Phillips, MI New, A Liebow, K Fitzgerald, W Querbes and RJ Desnick. (2014). RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A 111:7777-7782.
100. Chan A, A Liebow, M Yasuda, L Gan, T Racie, M Maier, S Kuchimanchi, D Foster, S Milstein, et al. (2015). Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acid 4:e263.
101. Sardh E, P Harper, M Balwani, P Stein, D Rees, J Bloomer, DM Bissell, R Desnick, C Parker, et al. (2018). Phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran, an investigational RNA interference (RNAi) therapeutic, in patients with acute intermittent porphyria, http://alnylam.com/wp-content/uploads/2018/04/EASL-Ph1-OLE-Capella-FINAL04142018.pdf Accessed on April 23, 2018.
102. Gouya L, JR Bloomer, M Balwani, DM Bissell, DC Rees, UStölzel, JD Phillips, R Kauppinen, JG Langendonk, et al. (2018). EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyrias (AHPs) with recurrent attacks, http://alnylam.com/wpcontent/uploads/2018/04/EASL-Explore-Capella-FINAL-04142018.pdf Accessed on April 23, 2018.
103. Negrier C, MV Ragni, P Georgiev, T Lissitchkov, H Van Nguyen, K Madigan and KJ Pasi. (2018). Perioperative management in patients with hemophilia receiving Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia, http://alnylam.com/wpcontent/uploads/2017/12/ASH-2017-Negrier-FINAL.pdf Accessed on April 23, 2018.
104. Pasi KJ, S Rangarajan, P Georgiev, T Mant, MD Creagh, T Lissitchkov, D Bevan, S Austin, CR Hay, et al. (2017). Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 377:819-828.
105. Pasi KJ, P Georgiev, T Mant, MD Creagh, T Lissitchkov, D Bevan, S Austin, CR Hay, I Hegemann, et al. (2017). Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia a or b with and without inhibitors, http://alnylam.com/wp-content/uploads/2017/07/ISTH-2017-Pasi-Fitusiran-OLE-CAPELLA-Deck-vFINAL-2017.07.10-1.pdf Accessed on April 23, 2018.
106. Strat AL, CM Ghiciuc, CE Lupusxoru and F Mitu. (2016). New class of drugs: therapeutic RNAi inhibition of PCSK9 as a specific LDL-C lowering therapy. Rev Med Chir Soc Med Nat Iasi 120:228-232.
107. Gaudet D. (2016). Novel therapies for severe dyslipidemia originating from human genetics. Curr Opin Lipidol 27: 112-124.
108. Ray KK, U Landmesser, LA Leiter, D Kallend, P Wijngaard, RS Wright and JJP Kastelein. (2017). Impact of a 1- or 2-dose starting regimen of Inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year, http://clinicaltrialresults.org/Slides/ESC2017/ORION-1-Ray.pdf Accessed on April 23, 2018.
109. Ray KK, U Landmesser, LA Leiter, D Kallend, P Wijngaard, RS Wright and JJP Kastelein. (2017). LDL-C reduction from 6 to 9 months following single or second injections of inclisiran, a novel siRNA compound, http://alnylam.com/web/assets/ACC-Ray-401-18-ORION-1-031717.pdf Accessed on April 23, 2018.
110. Liebow A, X Li, T Racie, J Hettinger, BR Bettencourt, N Najafian, P Haslett, K Fitzgerald, RP Holmes, et al. (2017). An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol 28:494-503.
111. Carney EF. (2016). Stones: a novel RNAi therapy for PH1. Nat Rev Nephrol 12:508.
112. Frishberg Y, W van't Hoff, S Hulton, P Haslett, DV Erbe, T McGregor and G Deschênes. (2018). A phase 1/2 trial of lumasiran (ALN-GO1), an investigational RNAi therapeutic for primary hyperoxaluria type 1, http://alnylam.com/wpcontent/uploads/2017/11/Lumasiran-ASN-Capella-Slides-FINAL11032017.pdf Accessed on April 23, 2018.
113. Alnylam. (2017). Alnylam initiates phase 2 clinical study of cemdisitan (ALN-CC5) in patients with atypical hemolytic-uremic syndrome (aHUS), http://investors.alnylam.com/news-releases/news-release-details/alnylaminitiates-phase-2-clinical-study-cemdisiran-aln-cc5-0 Accessed on April 23, 2018.
114. Rozema DB, DL Lewis, DH Wakefield, SC Wong, JJ Klein, PL Roesch, SL Bertin, TW Reppen, Q Chu, et al. (2007). Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 104:12982-12987.
115. Wong SC, JJ Klein, HL Hamilton, Q Chu, CL Frey, VS Trubetskoy, J Hegge, D Wakefield, DB Rozema and DL Lewis. (2012). Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther 22:380-390.
116. Wooddell CI, DB Rozema, M Hossbach, M John, HL Hamilton, Q Chu, JO Hegge, JJ Klein, DH Wakefield, et al. (2013). Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21:973-985.
117. Yuen MF, HLY Chan, SHK Liu, B Given, T Schluep, J Hamilton, CL Lai, S Locarnini, JY Lau, et al. (2015). ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B. Hepatology 62:1385A.
118. Yuen M-F, K Liu, BD Given, T Schluep, J Hamilton, C-L Lai, SA Locarnini, K Jackson, J Lau, et al. (2018). RNA interference therapy with ARC-520 injection results in long term off-therapy antigen reduction in treatment naïve patients with chronic HBV, http://ir.arrowheadpharma.com/static-files/5b205068-35a4-41c9-942e-cb5ed100c2b2 Accessed on April 23, 2018.
119. Buchanan J. (2016). Arrowhead stock falls after FDA places hold on clinical trial, https://xconomy.com/wisconsin/2016/11/09/arrowhead-stock-falls-after-fda-places-hold-onclinical-trial/ Accessed on April 23, 2018.
120. Wooddell C, R Zhu, H Hamilton, Q Chu, H Sternard, J Schumacher, T Schluep, M Seefeld, Z Li and B Given. (2018). Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection. J Hepatol 68:S18-S19.
121. Wooddell C, K Blomenkamp, H Chen, J Griffin, R Zhu, Q Chu, H Hamilton, J Hegge, D Christianson, et al. (2018). AROAAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposureresponse and efficacy in preclinical studies. J Hepatol 68:S82.
122. Dicerna. (2018). Corporate Overview, http://investors.dicerna.com/static-files/b0fe07db-a91e-4be5-a422-03d9fd6ab93e Accessed on April 23, 2018.
123. Webb C. (1963). The Graduate. The New American Library, ISBN 0743456459.